BioSpace News Archive

BioCapital

Who’s on Top: The Current Leaders in Biopharma Diversity

For BioSpace’s recent Ideal Employer report, life sciences professionals weighed in on the topic.

November 4, 2019
·
3 min read
·
Kymberlie Krieger
Business

Are Diversity and Inclusion Part of Your Organization’s Culture?

In the United States, an organization’s culture has been at the forefront of talent attraction and employee engagement initiatives for more than a decade.

November 4, 2019
·
4 min read
·
By Dana Dunbar SHRM-SCP
Drug Development

Sanofi’s Toujeo Proves Effective in Children and Adolescence for Type 1 Diabetes

It was the first randomized, controlled trial comparing Toujeo to Gla-100 in this patient population.

November 4, 2019
·
3 min read
·
Mark Terry
Business

Halozyme to Cut 55% of Workforce Following Pancreatic Cancer Drug’s Phase III Failure

Halozyme Therapeutics will halt development of a metastatic pancreatic cancer drug after it failed to demonstrate an improvement in overall survival in a Phase III trial.

November 4, 2019
·
2 min read
·
Alex Keown
Business

Cerecin strengthens its leadership position in CNS drug development by adding a biotech veteran to the executive team

Bruce Morimoto joins Cerecin as Vice President of Drug Development

November 4, 2019
·
3 min read
Pharm Country

New 3D Bioprinting Technique Utilizes Vasculature that Closely Simulates Human Skin

Researchers at Rensselaer Polytechnic Institute developed a technique for 3D printing living skin that also has blood vessels.

November 4, 2019
·
2 min read
·
Mark Terry
Tecentriq Continues Upward Projection by Proving Efficacy Over and Over

The versatile drug currently treats locally advanced or metastatic urothelial carcinoma, metastatic non-small cell lung cancer, metastatic triple-negative breast cancer, and extensive-stage small cell lung cancer.

November 4, 2019
·
3 min read
·
Elizabeth Glasure
Policy

ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx

Endorsement of pivotal development program in recurrent glioblastoma (rGBM) from both EMA and FDA

November 4, 2019
·
4 min read
Business

White House Nominates MD Anderson’s Stephen Hahn as Next FDA Commissioner

Late Friday, President Donald Trump put forth Hahn’s name to take over the top spot of the nation’s regulatory agency.

November 4, 2019
·
2 min read
·
Alex Keown
ADC Therapeutics Announces Publication of ADCT-402 Data in Clinical Cancer Research

Data support potential of ADCT-402 to become an important treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma

November 4, 2019
·
5 min read